Abstract
Impact of COVIDâ€19 on Venous Thromboembolism in Inflammatory Bowel Disease Hospitalizations: A Propensityâ€Matched Analysis Patients diagnosed with Inflammatory bowel disease (IBD) face a notably higher risk of venous thromboembolism (VTE), leading to significant health challenges. Similarly, coronavirus disease 2019 (COVIDâ€19) is associated with an increased susceptibility to thrombosis. We aimed to assess the impact of COVIDâ€19 on the risk of developing VTE in patients with an underlying diagnosis of IBD.We retrospectively analyzed the National Inpatient Sample (NIS) 2020â€"21 to identify adult patients with IBD admitted with or without a principal diagnosis of COVIDâ€19. We divided these patients into three groups (without COVIDâ€19, with uncomplicated COVIDâ€19, and with complicated COVIDâ€19). Hospitalization characteristics, inâ€hospital mortality, odds of VTE, healthcare burden, and complications were compared.IBD patients with complicated COVIDâ€19 infection had significantly higher odds of VTE (OR 5.60, 95% C.I. 3.63â€"8.65, p 0.001), an increase in odds of mortality (OR 29.13, 95% C.I. 22.59â€"37.57, p 0.001), higher healthcare resource utilization (including length of stay and total hospitalization charges), and worse secondary outcomes (like acute kidney injury and pancytopenia), compared to IBD patients without COVIDâ€19. IBD patients with uncomplicated COVIDâ€19 also had higher odds of VTE (OR 1.81, 95% C.I. 1.39â€"2.36, p 0.001) than those without COVIDâ€19; however, there was no difference in mortality or length of stay between these two groups, and those with uncomplicated COVIDâ€19 had lower average total hospitalization charges.Patients with both complicated and uncomplicated COVIDâ€19 were associated with higher odds of VTE compared to those without COVIDâ€19. Patients with complicated COVIDâ€19, in addition, also had higher odds of mortality.